Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of$ 0.36. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -47.22%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 0.33 per share when it actually produced a loss of $0.34, delivering a surprise of -3.03%.Over the last four quarters, ...